Clinical Trial Update: Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 trials evaluated droxidopa (L-threo-3,4-dihydroxyphenylserine) for improving orthostatic hypotension and other non-motor symptoms in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• Droxidopa (Droxidopa)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple System Atrophy | Phase 2, Phase 3 | Status: COMPLETED